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Resistance to endocrine therapy is common among breast cancer patients with estrogen receptor alpha-positive (ER+) tumors
and limits the success of this therapeutic strategy. While the mechanisms that regulate endocrine responsiveness and cell fate
are not fully understood, interferon regulatory factor-1 (IRF1) is strongly implicated as a key regulatory node in the underlying
signaling network. IRF1 is a tumor suppressor that mediates cell fate by facilitating apoptosis and can do so with or without
functional p53. Expression of IRF1 is downregulated in endocrine-resistant breast cancer cells, protecting these cells from IRF1-
induced inhibition of proliferation and/or induction of cell death. Nonetheless, when IRF1 expression is induced following IFNγ
treatment, antiestrogen sensitivity is restored by a process that includes the inhibition of prosurvival BCL2 family members and
caspase activation. These data suggest that a combination of endocrine therapy and compounds that eﬀectively induce IRF1
expression may be useful for the treatment of many ER+ breast cancers. By understanding IRF1 signaling in the context of





women were diagnosed with invasive breast cancer, and
approximately 40,000 women died from the disease in the
United States alone [1]. Despite the advances in treatment,
earlierdetectionthroughscreening,andincreasedawareness,
breast cancer remains the second most diagnosed cancer
in women [2]. Approximately 70% of tumors will be
estrogen receptor-α positive (ER+). Randomized trials and
large meta-analyses clearly indicate that all breast cancer
patients derive a statistically signiﬁcant survival beneﬁt
from endocrine therapy and chemotherapy [3], with the
antiestrogen (AE) tamoxifen (TAM) being among the most
eﬀectivesingleagents.Thissurvivalbeneﬁtreﬂectstheability
of these agents to drive cells down an irreversible cell death
pathway [4]. Yet, advanced ER+ breast cancer remains an
incurable disease, and improvements in overall survival rates
for these women have been relatively modest during this
timeframe [5].
Endocrine therapy is generally administered as an
antiestrogen, such as TAM or fulvestrant (FAS; Faslodex;
ICI 182,780), or as an aromatase inhibitor (AI) including
letrozole or exemestane. TAM is the most frequently used AE
and signiﬁcantly reduces the risk of recurrence and death in
patientswithER+disease[6].FiveyearsofTAMisastandard
treatment for both premenopausal and postmenopausal
women with ER+ breast cancer [7]. Mechanistically, TAM
is a selective estrogen receptor modulator (SERM) that
competes with the endogenous ER substrate (17β-estradiol)
for binding to the receptor protein [8]. TAM induces a
conformationalchangeinthereceptorthat,inturn,represses
ER transcriptional activity [9]. While TAM has been the
treatment of choice for over three decades, third-generation
AIs have demonstrated a greater disease-free beneﬁt than
TAM and are often now the ﬁrst line endocrine therapy of
choice for postmenopausal women with ER+ breast cancer
[10]. Newer antiestrogens, such as the selective estrogen
receptor down regulator fulvestrant, do not exhibit the
partialagonistactivitiesofSERMsandareeﬀectivetreatment
options after relapse on TAM [11]. FAS has been shown2 International Journal of Breast Cancer
to be as eﬀective as the AI anastrozole in postmenopausal
women with advanced breast cancer resistant to TAM
[12].
2.EndocrineResistance
Despite AIs and AEs being key modalities in the treatment
of ER+ breast cancers, the inability of these therapies
to cure all women with ER+ disease remains a major
challenge to the clinical and research communities [13]. In
the case of TAM, de novo (intrinsic) or acquired resistance
limits the eﬃcacy of treatment in many patients with ER+
disease. Approximately 50% of ER+ tumors are de novo
resistant. Moreover, some tumors may become resistant to
endocrine therapies despite the continued presence of ER;
a small proportion may also become ER-negative (ER−).
Consequently, we fail to predict responsiveness to endocrine
therapy in 66% of ER+/progesterone receptor (PgR) neg-
ative, 55% of ER−/PgR+, and 25% of ER+/PgR+ tumors
[8].Clearly,betterpredictorsofendocrineresponsivenessare
required.
Most TAM-resistant tumors retain detectable levels of
ER expression, and many of these will respond to second or
thirdlinehormonaltherapies[9].Forpatientswithadvanced
breast cancer, FAS is beneﬁcial following progression on
TAM therapy [14]. Currently, FAS is the only FDA approved
drug to treat advanced breast cancer in postmenopausal
women who previously progressed on other antiestrogens.
However, a signiﬁcant number of patients will also develop
resistance to FAS [15]. The inability to fully modify these
negative outcomes reﬂects an incomplete understanding of
the signaling events eﬀecting cell proliferation, survival,
and hormonal regulation. Estrogen independence and AE
resistance are complex phenotypes, and it is unlikely that a
single gene/signaling pathway drives endocrine resistance in
ER+ tumors.
Drug resistance arises from a cell’s inability to induce
signaling down an irreversible cell death pathway. There-
fore, understanding the key signaling aspects of resistance
and how they are balanced, ultimately leading to cell
death/survival, is an important research goal [13]. Several
genes associated with survival despite antiestrogen treat-
ment have been identiﬁed from gene expression microar-
rays between antiestrogen-responsive (MCF7/LCC1) and—
resistant variants (MCF7/LCC9) of the MCF7 human breast
cancer cell line [16]. One transcription factor that is vital
in the cell death/survival regulatory network is interferon
regulatory factor-1 (IRF1), which is downregulated in the
resistant cell line. These data and others suggest that
the downregulation of IRF1 protects breast cancer cells
from IRF1-induced inhibition of cell proliferation and/or
induction of apoptosis [16, 17]. In the present review paper,
we summarize the role of IRF1 in endocrine responsiveness
and how IRF1 aﬀects the molecular signaling that regulates
cell fate. By understanding the contribution of IRF1 to
cellular growth and tumor suppression, we will further our
knowledge on the signaling pathways of malignant diseases,
which could lead to the development of novel and more
eﬀective therapeutic strategies for ER+ breast cancers.
3.IRF1
3.1. Structure of the IRF1 Gene/Protein. IRF1 was initially
characterized for its role in the transcriptional activation
of type I interferon (IFN) genes. During a study on the
regulation of the IFN-β gene by a virus, a factor that was
called IRF1 was found to bind to the IFN-β gene promoter
and to regulate its transcription. Ten splice variants of IRF1
have been identiﬁed and are labeled as splice patterns 1–
10 [18]. IRF1 is now recognized as an essential player in
many facets of the immune response and oncogenesis [19].
Since the discovery of IRF1 in 1988, there are now nine
known IRF family members in humans and mice: IRF1,
IRF2,IRF3,IRF4(alsoknownasPIP,LSIRF,orICSAT),IRF5,
IRF6, IRF7, IRF8 (ICSBP), and IRF9 (ISGF3γ)[ 19]. Each
IRF contains a well-conserved N-terminal DNA-binding
domain (DBD) of approximately 120 amino acids and ﬁve
conserved tryptophan repeats [20]. The IRF DBD has a
helix-turn-helix architecture that recognizes a speciﬁc DNA
sequence corresponding to the IFN-stimulated response
element (ISRE; G(A)AAAG/CT/CGAAAG/CT/C) [21].
A single point mutation (P325A) in the C-terminal
region of IRF1 (multifunctional-1; Mf1; residues 301–325)
increases both IRF1’s ability to regulate its own transcription
and rate of degradation [22]. We have also reported a novel
single nucleotide polymorphism in the IRF1 gene (A4396G).
IRF1-A4396G is more frequent in human breast cancer cell
lines than in the general population and is more frequently
expressed in African American than Caucasian women [23].
Subsequent to the identiﬁcation of IRF1, a structurally
similar molecule, IRF2, was isolated by its ability to cross-
hybridize with the IRF1 cDNA (Figure 1)[ 24]. The two
factors show 62% homology in their N-terminal regions
(spanning the ﬁrst 154 residues), whereas the rest of the
family members exhibit only 25% similarity [24]. While
IRF1 is characterized by an abundance of acidic amino acids
and serine-threonine residues in its carboxy-terminal region
(transcriptional activation domain), IRF2 is relatively rich
in basic residues [24]. When activated by IFN signaling,
both IRF1 and IRF2 bind to the same DNA element,
known as IRF-E, which is almost identical to the ISRE [20].
DespitetheirsimilarDBDs,thesetwofactorsarefunctionally
distinct. IRF1 mRNA is dramatically upregulated upon viral
infection or IFN stimulation [24]. A high level of IRF1,
in turn, results in the induction of endogenous IFN-α
and IFN-β in a variety of cell types, while IRF2 represses
IRF1 transcriptional activation [25]. The IRF1 protein is
also very unstable (half life ∼30min) compared with IRF2
(half-life ∼8hrs) [26]. These ﬁndings suggest respective
functional activator and repressor roles for IRF1 and IRF2
for the regulation of the IFN-α/β genes. Further studies
demonstratedmarkedlydiverserolesforIRFfamilymembers
including how they contribute to the regulation of key
functions in the development of immune cells and in the
control of oncogenesis.
3.2. Role of IRF1 in IFN Signaling. IRF1 is expressed at
low levels in unstimulated cells and is activated by many
cytokines including type I (IFNα,I F N β, and others) andInternational Journal of Breast Cancer 3








Figure 1: Domain structures of IRF1 and IRF2. IRF1 and IRF2
are composed of a DNA-binding domain (DBD; N-terminus) and
a regulatory domain (C-terminus). The DBD is characterized by
ﬁve tryptophan residues each separated by 10–18 amino acids.
IRF1 and IRF2 also contain an IRF association domain (IAD). For
IRF1, activity depends on phosphorylation, whereas IRF2 contains
a repression domain (red). The size of each IRF1 (in amino acids;
aa) is also indicated. C: carboxyl terminus; N: amino terminus.
II (IFNγ) interferons, tumor necrosis factor-α (TNF-α),
retinoic acid, interleukin-1 (IL-1), IL-6, and viral infec-
tion [19]. Initial signaling is mediated through the Janus-
activated kinase-signal transducer and activator of transcrip-
tion (JAK/STAT1) pathway, leading to the activation of the
IRF1 promoter by the Stat and NF-κB transcription factors
[20, 27]. When a signal is transduced through the IFN
receptor, phosphorylated STAT1 translocates to the nucleus
where it induces the transcription of primary IFNγ response
genes [20]. Stat1-deﬁcient cells no longer respond to IFN
stimulation by inducing IRF1 expression [28].
3.3. Regulation of IRF1 Expression. As IRF1 is a short-
lived protein, rapid changes in steady-state levels occur in
response to stimuli such as DNA damage or viral infection
[26, 29]. The precise mechanism that regulates IRF1 stability
is unknown, but IRF1 is polyubiquitinated by the E3
ubiquitin ligase and then degraded by the 26S proteasome
[30]. In unstressed cells, IRF1 is chaperoned by the E3
ligase and the C-terminus of heat-shock cognate (Hsc70)-
interacting protein (CHIP). In stressed cells, a complex
forms between CHIP and IRF1, leading to an increase in
ubiquitination of IRF1 and a decrease in its steady-state
levels[31].Additionally,theC-terminalregionofIRF1(Mf1)
was identiﬁed as the regulatory domain that modulates
target gene expression and determines the rate of IRF1
protein degradation. Without this enhancer region, the IRF1
protein becomes more resistant to both degradation and
ubiquitination in proliferating cells [29]. IRF1 is also serine
phosphorylated by casein kinase II (CKII), protein kinase A
(PKA), and protein kinase C (PKC) at two clustered regions
(between amino acids 138–150 and 219–231), which may
also have an eﬀe c to nI R F 1r e g u l a t i o n[ 32].
IRF1 protein turnover and activation is also regulated
by its multifunctional Mf1 domain. Recruitment of heat-
shock protein (Hsp70) to the Mf1 domain leads to the
further recruitment of Hsp90, which results in an increase
in endogenous IRF1 protein [33]. IRF1 is a member of
a class of proteins considered to be unstructured [34],
which allows it to interact with multiple proteins [35]. In
addition to nucleophosmin (NPM1), which can inhibit IRF1
function, the interaction between IRF1 repressors, YB-1 (Y-
box protein) and TRIM28 (tripartite motif-containing 28),
which are both overexpressed in various cancer types, has
also been reported [35]. The presence of multiple IRF1
regulating proteins and its short protein half life suggest
the presence of several redundant regulatory interactions,
often the mark of a central functional activity for the control
of critical cellular functions. Perhaps this is not surprising,
given IRF1’s ability to aﬀect cell fate decisions.
3.4. Biological Functions of IRF1. IRF1 has remarkable
functional diversity and controls the transcription of genes
involved in mediating antiviral, immunomodulatory, and
antiproliferative eﬀects [19]. Events downstream of IRF1
activation include changes in major histocompatibility com-
plex (MHC) class I and interferon expression, inducible
nitric oxide synthase (iNOS) expression, the development of
CD8+ Tcells,inductionofIL-12andThelperdiﬀerentiation,
and natural killer (NK) development [36]. In addition to
having critical functions in the development and activation
of immune cells, IRF1 is also involved in cell cycle regulation
and apoptosis in response to a variety of stressors [17]. For
instance, IRF1 coordinates expression of the immunopro-
teasome [37], regulates human telomerase activity [38, 39],
and controls vital aspects of DNA damage repair [40, 41].
IRF1 can regulate signaling that leads to the induction of
apoptosis [42], which it can achieve with or without the
induction of the cell cycle inhibitors, p21cip1 [17]o rp 2 7 kip1
[43], and through the activation of caspases (CASP)-1 [40],
CASP-3 [44], CASP-7 [45, 46], CASP-8 [44, 46], and/or Fas
ligand [47]. IRF1 also induces apoptosis in a p53-dependent
or-independent manner [40, 42]. Thus, IRF1 is capable of
functioning in multiple cellular contexts. For example, p53 is
frequently mutated in many cancers including 30% of breast
cancers, but this loss of p53 function does not necessarily
abrogate IRF1’s capacity to regulate cell fate decisions [48].
4. IRF1 in Tumor Suppression
4.1. IRF1 as a Potential Tumor Suppressor. Ac r i t i c a lf a c e to f
IRF1’s function in host defense is the regulation of onco-
genesis. The ﬁrst studies to highlight IRF1’s role in tumor
suppression and cell cycle control were established using
IRF1−/− mouse embryonic ﬁbroblasts (MEFs). IRF1−/−
MEFs are deﬁcient in their ability to undergo DNA-damage
cell cycle arrest, a phenotype similar to that observed in
MEFs lacking the tumor suppressor p53 [17]. Furthermore,
transcriptional induction of p21cip1 following gamma irra-
diation is dependent on both IRF1 and p53 [17]. Several
other reports have also elucidated the involvement of IRF1 in
cell growth eﬀects [49, 50]. IRF1 can eliminate precancerous
cells through apoptosis induced by DNA damage or other
stimuli. For instance, wild-type MEFs require two or more
oncogenic mutations for transformation, whereas a “single
hit” with c-Ha-ras induces transformation in IRF1−/−
MEFs [51]. In this situation, apoptosis is dependent upon
both p53 and IRF1. In contrast, DNA damage-induced
apoptosis in mitogenically activated mature T lymphocytes4 International Journal of Breast Cancer
is dependent on IRF1 but independent of p53 [40]. These
studies demonstrate that IRF1 can mediate two crucial
compounds of neoplastic progression: apoptosis and cell
cycle arrest [44, 51].
4.2. IRF1 in Breast Cancer. The IRF1 locus at chromosome
5q31.1 was initially reported to be lost in a substantial
proportionofleukemiaandpreleukemicmyelodysplasiacells
[52]. IRF1 is also frequently deleted (loss of heterozygosity)
in esophageal [53] and gastric carcinoma (point mutation)
[54]. Approximately 11% of sporadic breast cancers exhibit
the loss of chromosome 5q12–31, the most frequent chro-
mosomelossdetectedbycomparativegenomichybridization
(CGH) [55]. Other studies report that approximately 30%
of neoplastic breast tissues have loss of IRF1 by immuno-
histochemical staining when compared with normal breast
epithelium [56]. Furthermore, high-grade ductal carcinoma
in situ (DCIS) or node-positive invasive ductal cancers were
less likely to express IRF1 and were much more likely to
have higher oncogenic IRF2 protein than normal [56]. CGH
also implicates IRF1 loss of heterozygosity (LOH) in 50%
of BRCA1 mutated breast cancer tumors [57, 58]. These
results are consistent with the hypothesis that loss of IRF1
expression in some breast cancers contributes to the loss of
a p p r o p r i a t eg r o w t hc o n t r o l .
Allelic loss of IRF1 is detected in 32% of women with
breast cancer (12/37 breast tissue specimens) [59]. This loss
of heterozygosity is associated with an increased risk of
recurrence and risk of death in the cases studied, strongly
implicating a tumor suppressive role for the IRF1 gene
in breast cancer [59]. Analyses of two publically available
ONCOMINE cancer gene microarray datasets also imply
an important tumor suppressive role for IRF1 in many
sporadic breast cancers. Protein expression studies show that
inbreasttumorsthemostprevalentlocationofIRF1iswithin
the cytosol (90%); this location suggests a transcriptionally
inactive form of IRF1 [60]. In contrast, 51% of the reported
tumors expressed IRF1 in the nucleus (in more than 50%
of the tumor cells), consistent with a potential to represent
a transcriptionally active form [60]. Thus, some breast
tumors may diﬀerentially regulate the activation of IRF1 by
controlling its subcellular localization. These observations
are consistent with a study reporting higher levels of
IRF1 protein in adjacent normal breast epithelium when
compared with high-grade DCIS or lymph node-positive
invasive ductal carcinoma of the breast [58]. Collectively,
these studies imply that some cells may bypass the growth
inhibitory mechanisms of IRF1 by down-regulating its
expression [60, 61]. This observation is supported by the
evidence that reduced IRF1 expression in breast cancer cells
is associated with low caspase activity, low apoptosis, and
ultimately, increased cell survival [16, 44, 62].
5. IRF1 inRegulatingAntiestrogen Resistance
IRF1 is a key mediator of cell death for the antiestrogens
fulvestrant [63] and tamoxifen [64]. The pathway described
in Figure 2 illustrates the mechanism by which IRF1










Figure 2: Putative IRF1-driven cell fate through BCL2 family
members, BIRC5, and caspases.
expressing a dominant negative IRF1 (dnIRF1), which lacks
the carboxyl-terminal transcriptional activation domain, do
not undergo FAS-induced cell death and are, in turn, less
sensitive to AEs [63]. Moreover, dnIRF1 expressing cells
result in the inhibition of CASP3/7 and CASP8, indicating
the primary antitumorigenic role of IRF1 is through the
promotion of apoptosis [44].
Furthermore, breast cancer cells that have acquired
resistancetoFASshowsigniﬁcantupregulationofmicroRNA
(miRNA)-221 and -222 expression [65]. Overexpression
of these two miRNAs aﬀects several oncogenic signaling
pathways, including the JAK/STAT and p53 pathway, sup-
ports ERα-independent proliferation, and promotes tumor
progression [65]. Thus, miRNA-221/222 may serve to down-
regulate the tumor suppressing eﬀects of IRF1 in breast
cancer cells following antiestrogen therapy. An acquired
resistance model involving aromatase inhibitors shows that
IRF1 expression is reduced in long-term estrogen deprived
MCF7 cells, indicating IRF1 is a key gene that is consistently
reduced in AE resistant breast tumors [66].
In ER+ breast cancer cells, Bouker et al. have shown that
IRF1 signaling reduces the rate of cell proliferation and the
incidenceofhumanbreastcancerxenograftsinathymicnude
mice[44].AdnIRF1blockstheeﬀectofparthenolide,asmall
molecule inhibitor of NF-κB, and synergistically interacts
with antiestrogens in vitro to reverse the antiestrogen-
resistance phenotype [67]. Moreover, antiestrogen resistant
breast cancer cells MCF7/LCC9 have greater BCL2 protein
expression compared to antiestrogen sensitive breast cancer
cells (MCF7/LCC1) [68]. LCC9 cells are more dependent
on BCL2 for their survival, since they exhibit a signiﬁcantly
greater growth inhibition by the small molecule BCL2
inhibitor HA 14-1 when compared with their LCC1 controls,
and the LCC9 antiestrogen-resistant cells also express lower
IRF1, indicating that a clear functional link exists betweenInternational Journal of Breast Cancer 5
IRF1, NF-κB activation, BCL2 expression, and ER+ breast
cancer cell fate [62, 68].
Functionally relevant interactions between IRF1 and at
least two diﬀerent members of the epidermal growth factor
receptors (EGFR) superfamily have been reported. EGFR
induces expression of IRF1 [69], and IRF1 also can regulate
EGFR expression [69], suggesting a possible role of IRF1
in EGFR overexpressing breast cancers. The coexpression of
EGFR and IRF1 appears key for the induction of apoptosis,
and blocking STAT5α with a dominant negative eliminates
the transcriptional synergy and ability of IRF1 and EGFR
to induce apoptosis [70]. Overexpression of EGFR (HER1)
is common in the subgroup generally referred to as “triple
negative breast cancer” (TNBC); these tumors lack the
ER, the PgR, and have normal human epidermal growth
factor 2 receptor (HER2/neu) levels. TNBCs are particularly
challenging to treat due to the lack of targeted therapy. Thus,
expression of IRF1 and the ability of EGFR:IRF1 to aﬀect cell
death may be important in TNBC.
IRF1 may play an important role in another breast
cancer subgroup, the HER2-ampliﬁed breast cancers. HER2
overexpressing breast cancer has a generally poor progno-
sis, with approximately 35% of cases responding to the
HER2-targeted therapy, Herceptin [71]. The importance
of interactions between IRF1 and HER2/neu are less well
described. For example, IRF1 expression becomes consti-
tutively activated in 3T3 cells transduced with HER2/neu
[72]. IFNγ induces IRF1 in MMTV-neu transgenic mice
and leads to apoptosis [73] .S e v e r a lo b s e r v a t i o n sh a v el e d
to the hypothesis that breast cancer patients with HER2/neu
overexpression may beneﬁt less from TAM than those whose
tumors with low expression of this oncogene. For example,
TAM acts similarly to estrogen withdrawal in MCF7 cells
transfected with the HER2/neu oncogene [74]. However, the
true relationship remains controversial, since a recent meta-
analysis found no association between TAM responsiveness
and HER2/neu expression. In contrast, a beneﬁt for both
anthracycline and taxane-based polychemotherapies shows
a clear association with Her2/neu status [75]. Given the
close relationship between IRF1 and EGFR family members,
studies of the role of IRF1 in modifying responsiveness to
taxanes and anthracyclines in the context of triple negative
and Her2/neu breast cancers seem warranted.
6.IRF1InducesCellDeaththroughApoptosis
Cell signaling to aﬀect an irreversible cell death results
in one or more forms of cell death including apoptosis
(programmed cell death 1; PCD1), autophagy (PCD2), and
necrosis (PCD3) [76, 77]. In the context of endocrine
responsive breast cancers, it is important to understand the
underlying mechanism that IRF1 uses to mediate tumor
suppressive activity. A recent study by Ning et al. shows how
combined IFNγ and FAS treatment increases the expression
and nuclear translocation of IRF1 [62]. AE sensitivity is
restored in AE-resistant breast cancer cells through an
IRF1-dependent increase in mitochondrial outer membrane
permeability and activation of the intrinsic apoptotic path-
way [62]. Apoptosis is then executed by selected caspases
including CASP7, CASP8, and CASP9 [62, 78]. Moreover,
IRF1-induced apoptosis is ligand independent but requires
a fas-associated death domain (FADD)/CASP8 complex that
forms intracellularly [79]. Members of the TGFβ family,
which have long been implicated in endocrine resistance
[80], also induce IRF1 expression that can lead to apoptosis
in breast cancer cells [61]. Overexpression of IRF1 in breast
cancer cells can induce apoptosis, which is consistent with its
tumor suppressive activity [68].
BCL2 family proteins have either pro- (including BAD,
BAK, BID, BAX, BID), or antiapoptotic activities (such as
BCL2, BCLW, and BCLXL) and are functionally involved in
the regulation of cell fate [81]. IRF1 mediates cell death,
speciﬁcally apoptosis, by signaling through several BCL2
family members and caspases [62, 78]. IRF1 can increase
expression of proapoptotic BAK, BAX, BIK, while decreasing
expression of the antiapoptotic BCL2 and BCLW [62].
Moreover, enhanced IRF1 expression in breast cancer cells
down-regulates the inhibitor of apoptosis protein, survivin
(BIRC5) [82]. Reduced expression of antiapoptotic BCL2
members and survivin, with an increase in proapoptotic
BCL2 protein expression, leads to an alteration in mitochon-
drial membrane permeability, release of cytochrome c,a n d
ultimately apoptosis executed by selected caspases [62]. We
propose a novel signal transduction pathway operating in
breast cancer (Figure 2). In this pathway, IRF1 plays a central
roleinregulatingexpressionofBCL2members,survivin,and
caspases, thus, determining the cell fate decision to live or to
undergo apoptosis.
The regulation of several BCL2 family members is
also dependent on NF-κB, a transcription factor critical
in the regulation of cell proliferation and in resistance to
cytotoxic drugs [83]. NF-κB is directly implicated in IFNγ
signaling. For example, NF-κB expression and activation is
signiﬁcantly increased in MCF7/LCC9 cells when compared
to the parental, antiestrogen sensitive MCF7/LCC1 breast
cancer cells; NF-κB can form functional heterodimers with
IRF1 that regulate the expression of genes through an
IFNγ activation site (GAS)/kappaB promoter element [84].
Increased NF-κB activation is functionally associated with
conferring an antiestrogen resistant phenotype, which it
does in part by modulating CASP8 activity, mitochondrial
function, and apoptosis. Interestingly, the activities of NF-κB
appeartoactbyincreasingBCL2expression[85,86],whereas
this expression is inhibited by IRF1; endogenous IRF1
expressionisreducedinthesecellsindicatingthatthebalance
b e t w e e nI R F 1a n dN F - κB may be critical in determining
cell fate. These activities are likely independent of IRF1:NF-
κB heterodimer formation [87], unless the primary role of
these in the endocrine resistant phenotype is to sequester
IRF1. The upregulation of NF-κB expression in resistant cells
would likely leave suﬃcient NF-κB, in excess of that bound
to IRF1, free to regulate its prosurvival signaling.
The combination of IFNγ and FAS reduces NF-κB
protein expression and transcriptional activation through
the induction of IRF1 [62]. In addition to NF-κB, NPM1
is also signiﬁcantly overexpressed in MCF7/LCC9 cells [16],
and NPM1 binds and inhibits IRF1 function [88]. Thus,
NPM1 may act by blocking/eliminating a caspase cascade6 International Journal of Breast Cancer
in breast cancer cells through its ability to reduce IRF1 and
signaling to apoptosis [16].
STAT1, a transcription factor upstream of IRF1 and
mediator of IFN signaling, is also considered a tumor
suppressor gene [89]. Protein levels of STAT1 and phos-
phorylated STAT1 are substantially increased with IFNγ
treatment, leading to an increase in IRF1 [62, 90]. Moreover,
Stat1 and IFNγ receptor null mice show spontaneous
tumor growth when either exposed to methylcholanthrene,
or are bred into a p53-deﬁcient background [91]. STAT1
also has a tumor suppressive role in mammary epithelium
in ERBB2/neu-induced breast cancer [89]. These studies
provide greater insight into the cell-speciﬁc roles of IFN and
STAT1 signaling, ultimately eﬀecting IRF1 induction.
7. ClinicalImplications
The ability of interferons to sensitize breast cancer cells to
TAM was shown over 20 years ago. Van den Berg et al.
showedthatthecombinationofIFNαandTAMhadagreater
antiproliferative eﬀect on ZR-75-1 breast cancer cells than
either drug alone [92]. IFNα,I F N β,a n dI F N γ have each
been used in the treatment of breast cancer either to induce
antiestrogen sensitivity and/or stimulate cellular immunity
[93]. Pilot studies suggest that IFNβ can improve clinical
beneﬁt and/or overall survival in patients with metastatic
breast cancer and will be tested in phase III clinical trial
[93]. Although mixed results have been shown with IFNα
as an antitumor agent, IFNβ and IFNγ, alone or combined
with an antiestrogen, have shown to be eﬀective in increasing
hormonal dependency and overcome TAM resistance [94].
The pegylation (covalent attachment of polyethylene glycol
molecule to a protein) of IFNα also induces IRF1-mediated
signaling and sensitizes melanoma cells to chemotherapy
[95]. Pegylated IFNα is currently being used in monotherapy
[96] and in combination with chemotherapy for several
diﬀerent types of cancers [97, 98].
Restoring IRF1 expression or controlling its modulation
may be useful for the treatment of ER-positive breast
tumors that have acquired resistance to endocrine therapy.
Therefore, a clear understanding of IRF1 signaling and how
it contributes to cell death is necessary for the discovery of
new drug candidates and better predictors of how tumors
will respond to endocrine therapy.
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